Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results

Go back to Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results

Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance

May 5, 2015 4:21 PM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.40, $0.01 better than the analyst estimate of $0.39. Revenue for the quarter came in at $180 million versus the consensus estimate of $183.3 million.

Myriad Genetics sees FY2015 EPS of $1.44-$1.46, versus prior guidance of $1.50-$1.55 and the consensus of... More